IPO Premiums
IPO calendar
ABListed

Anthem Biosciences Limited

Bookbuilding IPO · NSE, BSE

Price band
₹540 - ₹570
Lot size
26 shares
Issue amount
₹3,395 cr
Total subscription
63.89×
Current price₹808.5
Listing price ₹723.05
Watch live price ↗
Opens
14 Jul 2025
Closes
16 Jul 2025
Allotment
17 Jul 2025
Listing
21 Jul 2025

Offer at a glance

Issue overview

Issue size
5,95,61,404 shares
Face value
₹10 per share
Minimum investment
₹14,040
Fresh issue
₹0 cr
Offer for sale
₹3,395 cr
Registrar
Kfin Technologies Limited
Listing exchange
NSE, BSE
Maximum investment
₹0
Issue type
Bookbuilding IPO
Shares before issue
55,90,77,100
Shares after issue
0

Lot sizes

CategoryLotsSharesAmount
Retail126₹14,820
sHNI14364₹2,07,480
bHNI681,768₹10,07,760

Share reservation

Retail34.91%
NII(HNI)14.96%
QIB19.95%
Employees0.27%

Subscription & GMP

Subscription by category

Total subscribed63.89×

Missing multiples are calculated from bids and offered shares when available.

QIB192.8×
NIB44.71×
HNIs(10L +)51.66×
HNIs (2-10L)30.82×
RETAIL5.96×
EMPLOYEES7×

GMP history

089.517930 Jun: ₹01 Jul: ₹02 Jul: ₹04 Jul: ₹08 Jul: ₹609 Jul: ₹9610 Jul: ₹11311 Jul: ₹8712 Jul: ₹9414 Jul: ₹10915 Jul: ₹15616 Jul: ₹14417 Jul: ₹14018 Jul: ₹12819 Jul: ₹15521 Jul: ₹179
30 Jun₹17921 Jul

Application-wise demand

CategoryReserved applicationsApplied applications
RETAIL7,99,84047,63,378
HNIs(10L +)16,3238,43,183
HNIs (2-10L)8,1622,51,514

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
QIBs677.351,30,592.47
RETAIL1,185.367,059.33
NIB508.0122,712.77
HNIs 2+169.345,218.41
HNIs 10+338.6817,494.36
EMPLOYEES9.0463.31

Financial performance

Company financials

In Crores · Reported periods may include interim results.

Revenue & profitIn Crores
05001,0001,5002,000Mar-22 · Revenue: 1,280.24Mar-22 · Profit after tax: 405.54Mar-22Mar-23 · Revenue: 1,133.99Mar-23 · Profit after tax: 385.19Mar-23Mar-24 · Revenue: 1,483.07Mar-24 · Profit after tax: 367.31Mar-24Mar-25 · Revenue: 1,930.28Mar-25 · Profit after tax: 451.25Mar-25
RevenueProfit after tax

Key performance indicators

MetricMar-25Mar-24Mar-23
EPS8.046.486.75
ROE20.8220.0424.89
ROCE26.8825.7131.69
RONW20.8220.0324.93
PRE IPO(PE)000
POST IPO(PE)000

Values and labels as reported in the issue data.

Company information

Company profile

Founded in 2006, Anthem Biosciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides comprehensive services throughout the drug development process—from discovery to manufacturing. The company specializes in producing fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, vitamin analogues, and biosimilars. It supports the full journey of commercial molecules, right from initial research to market launch. By September 30, 2024, Anthem had built a global presence, serving more than 425 clients in over 44 countries, including key markets like the U.S., Europe, and Japan. Its clientele ranges from small biotech startups to major pharmaceutical companies. Anthem is actively engaged in research and development, with 196 projects underway at different stages, including discovery, early and late development phases, and commercial production. The company also focuses on innovation, holding 8 granted patents (1 in India and 7 internationally), along with 24 pending patent applications worldwide. The company’s workforce, as of September 2024, consists of 600 professionals, including skilled chemists, biologists, and engineers with expertise across various scientific and technical fields.

Strengths

  • End-to-end CRDMO capabilities across small and large molecules with integrated services from discovery to commercial manufacturing, making it the fastest-growing Indian CRDMO with presence in all three segments.
  • Focused business model targets emerging pharma and biotech firms needing external expertise, regulatory support, and scalable manufacturing.
  • Scalable and compliant manufacturing infrastructure with two cGMP facilities and 142 kL capacity (expanding to 182 kL), backed by major capital investments.

Risk factors

  • Regulatory compliance and inspection delays by authorities like USFDA and PMDA may disrupt manufacturing and impact revenue due to approval or compliance issues.
  • Heavy reliance on manufacturing units (Unit I, II, and upcoming Unit III) exposes the company to risks from delays, labor shortages, or material issues affecting CRDMO and specialty ingredient operations.
  • Exposure to hazardous materials increases operational risks despite safety upgrades, with potential for accidents, operational disruption, or damage to people and property.

Promoters

Ajay Bhardwaj

Ganesh Sambasivam

K Ravindra Chandrappa

Ishaan Bhardwaj

Registrar & documents

Lead manager

Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Jm Financial Limited, Nomura Financial Advisory And Securities (India) Private Limited , Securities (India) Private Limited

Registered office

No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099

+91 080 6672 400

[email protected]Company website ↗

Frequently Asked Questions

What is Anthem Biosciences IPO GMP today?

As of today, Anthem Biosciences IPO Grey Market Premium (GMP) is reported at +₹179 per share. Based on the upper price band of ₹570, the estimated listing price is ₹749 (+31.4% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.

What is the lot size and minimum investment for Anthem Biosciences IPO?

The minimum bid lot size for Anthem Biosciences IPO is 26 shares. At the cut-off price of ₹570 per share, retail investors need a minimum application amount of ₹14,820 per lot. Retail applicants can apply for a maximum of 13 lots (up to ₹2,00,000).

When will Anthem Biosciences IPO allotment status be announced?

The allotment status for Anthem Biosciences IPO is scheduled to be finalized on 17 Jul 2025. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Kfin Technologies Limited's official portal or via BSE/NSE allotment portals.

How can I check Anthem Biosciences IPO allotment status online by PAN?

To check Anthem Biosciences IPO allotment status: 1) Visit the registrar portal (Kfin Technologies Limited) or the BSE IPO allotment page. 2) Select 'Anthem Biosciences Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.

Explore More IPO Analysis & Live Tools

Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.

Regulatory Disclaimer: Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and does not represent a stock exchange transaction, guarantee, or investment advice. IPO Premiums is an informational and research portal and is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before applying for any IPO.